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Figure 1. Proposed Catalytic Mechanism of Rv1248c
(A) Following decarboxylation, the activated aldehyde derivative of a-ketoglutarate (a-KG) undergoes
condensation with glyoxylate (GLX) to form 2-hydroxy-3-oxoadipate (HOA). HOA spontaneously decar-
boxylates to form 5-hydroxylevulinate (HLA).
(B) Trapping method used to observe the HOA intermediate.
Chemistry & Biology
Previewswhich knockout mutants can not be
created. Since essential microbial gene314 Chemistry & Biology 17, April 23, 2010 ªproducts have often been targeted for
therapeutic development, this profiling2010 Elsevier Ltd All rights reservedmethod will ultimately aid in both the
assignment of promising, novel antimicro-
bial protein targets and deciphering the
vital biochemical function of those
targets.
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Insufficiency of oxygen supply tomammalian cells activates the transcription factor complex ‘‘hypoxia induc-
ible factor’’ (HIF). In this issue of Chemistry and Biology, Smirnova et al. (2010) report on the results of a high
throughput screen, which they have used to identify lowmolecular weight compounds that activate HIF even
in the presence of oxygen.A number of proteins are subjected to
a variety of posttranslational modifica-
tions, such as phosphorylation, ubiquiti-
nation, sumoylation, acetylation, and
others. Thus, in many cases, the require-
ments of cell metabolism can be met by
subtle changes of the protein structure.
Hydroxylation, a posttranslational modifi-
cation that introduces hydroxyl groups
(-OH) into an amino acid side chain, is
now recognized to be of major impor-tance. The first protein shown to undergo
hydroxylation was collagen, where hy-
droxyproline and hydroxylysine residues
add to themechanical stability of collagen
fibrils. A list of proteins documented to be
hydroxylated has grown significantly over
the last decade and includes, most impor-
tantly, a master transcriptional regulator
termed hypoxia-inducible factor (HIF).
The a-subunit of the transcription factor
complex HIF is modified in an oxygen-dependent manner by three prolyl
hydroxylase domain proteins, PHD1–3
(Epstein et al., 2001) and the asparaginyl
hydroxylase factor inhibiting HIF-1, FIH-1,
(Lando et al., 2002). While modification of
either of two distinct proline residues
leads to binding of the von-Hippel-Lindau
protein and rapid proteasomal destruc-
tion, asparaginyl hydroxylation abrogates
binding of the transcriptional coactivator
p300/CBP and thus inhibits function of
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This means that two distinct modes of HIF
activity regulation act in parallel, both of
which are oxygen-dependent (Webb
et al., 2009).
The PHDs and FIH-1 belong to a
superfamily of 2-oxoglutarate-dependent
dioxygenases. These enzymes differ with
respect to their peptide recognition se-
quence and thus their primary substrate.
However, all of them adopt the conforma-
tion of non-heme Fe2+ binding dioxyge-
nases and use molecular oxygen and
ascorbate as cosubstrates. Another im-
portant distinction between the enzymes
of this superfamily is their affinity to
molecular oxygen (Hirsila et al., 2003).
For example, the collagen hydroxylases
have a relatively high O2 affinity, making
them rather insensitive to changes in
tissue oxygenation. They appear to be
more sensitive to a lack of ascorbate,
which causes scurvy. In contrast, HIF-a
prolyl hydroxylases have a lower affinity
to oxygen, so that a reduction of tissue
oxygen supply reduces their activity. This
leads to an increased stability of HIF-a.
Actually, low oxygen affinity makes these
enzymes apt to function as cellular
oxygen sensors.
Hypoxia, i.e., a situation when cells are
not supplied with sufficient amounts of
oxygen, can occur in physiology. For
example, hypoxia is a significant stimulus
for blood vessel growth in the embryo
(Dunwoodie, 2009). In clinical medicine,
hypoxia is very relevant in many condi-
tions. For example, in anemia, the oxygen
transport capacity of the blood is re-
duced. Tissue hypoxia is also caused
when blood flow is impaired, as in athero-
sclerosis, or when rapidly proliferating
cells outgrow the oxygen supply pro-
vided, e.g., in a malignant tumor. Strik-
ingly, normal as well as malignant cells
respond to a lack of oxygen with the
activation of HIF. This transcription factor
complex is composed of two subunits:
the b-subunit is constitutively expressed,while the a-subunit is constantly pro-
duced but has a very short half-life in
the presence of oxygen. When oxygen
becomes limiting, the PHDs are inacti-
vated, which allows translocation of
HIF-a to the nucleus and transcriptional
activation of a celltype-dependent set of
target genes. The effects of HIF activation
include the release of erythropoietin that
stimulates the production of red blood
cells. HIF also promotes angiogenesis,
and a shift of cellular energy metabolism
away from mitochondrial respiration and
in favor of an increase in glycolysis and
anaerobic ATP generation. With respect
to pharmacological intervention, the mul-
titude of HIF effects hold promise and
threat at the same time. On the one hand,
it would be desirable to have a HIF-acti-
vating compound to stimulate erythropoi-
esis and angiogenesis in anemia and
ischemic disease, respectively. On the
other hand, however, it would be attrac-
tive to limit angiogenesis and thus blood
supply to tumors via HIF inhibition (Se-
menza, 2009).
In this issue, Smirnova et al. (2010)
report their results on the screen for HIF
activators that included 85,000 low
molecular weight compounds. For the
screen, the authors made use of the
molecular switch, which causes degrada-
tion of HIF-a in the presence of oxygen.
The DNA sequence of the oxygen depen-
dent degradation domain (ODD) of HIF-a
was fused to the firefly luciferase gene,
i.e., the feature of oxygen-dependent
instability was transferred to the luciferase
protein. When they transfected this artifi-
cial DNA into human neuroblastoma cells,
they were able to use ODD-luciferase
expression as an indicator of PHDactivity.
Any inhibitor of PHD-dependent HIF
degradation could now be identified by
an increased luciferase activity in the
presence of oxygen. With this approach,
Smirnova et al. (2010) identified novel
PHD inhibitors that work efficiently at
low micromolar concentration. Using inChemistry & Biology 17, April 23, 2010silico modeling, the authors provide com-
pelling evidence that their best com-
pounds act preferentially on PHDs as
compared to FIH-1 or other enzymes of
the same class. Clearly, these results are
encouraging.
One note of caution is, however, that
substrates of the PHDs other than HIF-a
have been identified, such as IkB kinase-
b (Cummins et al., 2006), and the large
subunit of RNA polymerase II (Mikhaylova
et al., 2008). Because the cell physiolog-
ical relevance of hydroxylation of alterna-
tive PHD substrates is somewhat unclear
so far, careful experimentation is war-
ranted to define whether PHD inhibition
is indeed a viable approach in vivo. Defi-
nitely, the results reported by Smirnova
et al. (2010) represent an important step
in this direction.
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